利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

49 条记录 (耗时 0.02 秒)

    RNA sequence-specific mediators of RNA interference
    1.
    发明公开
    RNA sequence-specific mediators of RNA interference 有权
    RNA-sequenzspezifische Mediatoren von RNA-Interferenz

    公开(公告)号：EP2028278A1

    公开(公告)日：2009-02-25

    申请号：EP08168152.0

    申请日：2001-03-30

    申请人： Whitehead Institute For Biomedical Research ,  Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. ,  Massachusetts Institute of Technology ,  UNIVERSITY OF MASSACHUSETTS MEDICAL CENTER

    发明人： Tuschl, Thomas ,  Sharp, Phillip A. ,  Zamore, Phillip D. ,  Bartel, David P.

    IPC分类号： C12Q1/68 ,  C12N15/10

    CPC分类号： C12N15/113 ,  A01K67/0336 ,  A01K2207/05 ,  A01K2217/075 ,  A01K2227/703 ,  A01K2267/03 ,  A61K38/00 ,  C07H21/02 ,  C12N15/1079 ,  C12N15/111 ,  C12N2310/14 ,  C12N2310/321 ,  C12N2310/53 ,  C12N2330/30 ,  C12Q1/66 ,  C12N2310/3521

    摘要： The present invention relates to a Drosophila in vitro system which was used to demonstrate that dsRNA is processed to RNA segments 21-23 nucleotides (nt) in length. Furthermore, when these 21-23 nt fragments are purified and added back to Drosophila extracts, they mediate RNA interference in the absence of long dsRNA. Thus, these 21-23 nt fragments are the sequence-specific mediators of RNA degradation. A molecular signal, which may be their specific length, must be present in these 21-23 nt fragments to recruit cellular factors involved in RNAi. This present invention encompasses these 21-23 nt fragments and their use for specifically inactivating gene function. The use of these fragments (or chemically synthesized oligonucleotides of the same or similar nature) enables the targeting of specific mRNAs for degradation in mammalian cells, where the use of long dsRNAs to elicit RNAi is usually not practical, presumably because of the deleterious effects of the interferon response. This specific targeting of a particular gene function is useful in functional genomic and therapeutic applications.

    摘要翻译： 本发明涉及果蝇体外系统，其用于证明dsRNA被加工成长度为21-23个核苷酸（nt）的RNA片段。 此外，当这些21-23个片段被纯化并加回到果蝇提取物时，它们在不存在长dsRNA的情况下介导RNA干扰。 因此，这些21-23个片段是RNA降解的序列特异性介质。 必须在这21-23个片段中存在可能是其特异性长度的分子信号，以招募涉及RNAi的细胞因子。 本发明包括这些21-23个片段及其用于特异性灭活基因功能的用途。 这些片段（或相同或相似性质的化学合成寡核苷酸）的使用使得能够靶向用于在哺乳动物细胞中降解的特异性mRNA，其中使用长dsRNA引发RNAi通常是不实际的，可能是因为有害影响 干扰素反应。 特定基因功能的特异性靶向在功能基因组和治疗应用中是有用的。

    HYBRIDIZATION AND FOOTPRINTING METHODS TO CHARACTERIZE THE INTERACTIONS OF 16S rRNA ANALOGUES FOR IDENTIFICATION OF NOVEL ANTIBIOTICS
    7.
    发明公开
    HYBRIDIZATION AND FOOTPRINTING METHODS TO CHARACTERIZE THE INTERACTIONS OF 16S rRNA ANALOGUES FOR IDENTIFICATION OF NOVEL ANTIBIOTICS 失效
    杂交和施加过程表示特征的和互动的16S rRNA模拟确定新的抗生素

    公开(公告)号：EP0804454A1

    公开(公告)日：1997-11-05

    申请号：EP95930926.0

    申请日：1995-08-23

    申请人： UNIVERSITY OF MASSACHUSETTS MEDICAL CENTER

    发明人： STERN, Seth ,  PUROHIT, Prakash

    IPC分类号： C12Q1

    CPC分类号： C12Q1/689 ,  C12Q1/6811 ,  C12Q1/6888

    摘要： The oligoribonucleotide analogs of the invention, as exemplified in the figure, are relatively small, three-dimensional structures derived from larger parental RNA molecules. The analogs include a first nucleic acid structure including one or more nucleotide sequences that are derived from a region of parental RNA, wherein in its native state, the region binds to a ligand, e.g., an aminoglycoside, with a parental RNA ligand binding pattern, and a second nucleic acid structure including one or more nucleotide sequences combined with the first nucleic acid structure to form the analog and provide the analog with a conformation that binds the ligand with a ligand binding pattern that is substantially identical to the parental RNA ligand binding pattern. These analogs can be used to identify novel therapeutic compounds.